Which closed-end funds own Ligand Pharmaceuticals Inc?
14 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $75.7M. Security type: debt security. Country: United States. CUSIP 53220KAJ7 · ISIN US53220KAJ79.
Holdings are historical filings (report dates Jun 30, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| CCD Calamos Dynamic Convertible & Income Fund | Convertible Securities | 1.08% | $10.1M | 9,500,000 par | $939M | 6.7% premium | Jul 31, 2026 |
| CHW Calamos Global Dynamic Income Fund | Taxable Bonds | 0.90% | $7.5M | 7,069,000 par | $836M | 9.5% discount | Jul 31, 2026 |
| CHI Calamos Convertible Opportunities & Income Fund | Convertible Securities | 0.90% | $12.3M | 11,500,000 par | $1.4B | 4.5% premium | Jul 31, 2026 |
| CGO Calamos Global Total Return Fund | Multi-Asset | 0.90% | $1.8M | 1,660,000 par | $197M | 10.8% discount | Jul 31, 2026 |
| CHY Calamos Convertible & High Income Fund | Convertible Securities | 0.88% | $12.8M | 12,000,000 par | $1.5B | 0.3% premium | Jul 31, 2026 |
| CSQ Calamos Strategic Total Return Fund | Multi-Asset | 0.41% | $19.9M | 18,680,000 par | $4.9B | 9.4% discount | Jul 31, 2026 |
| NCZ Virtus Convertible & Income Fund II | Convertible Securities | 0.41% | $1.9M | 1,770,000 par | $463M | 7.6% discount | Jul 31, 2026 |
| NCV Virtus Convertible & Income Fund | Convertible Securities | 0.39% | $2.3M | 2,215,000 par | $601M | 9.6% discount | Jul 31, 2026 |
| ACV Virtus Diversified Income & Convertible Fund | Convertible Securities | 0.37% | $1.4M | 1,320,000 par | $380M | 5.3% discount | Jul 31, 2026 |
| NIE Virtus Equity & Convertible Income Fund | Convertible Securities | 0.24% | $1.9M | 1,760,000 par | $786M | 9.5% discount | Jul 31, 2026 |
| AVK Advent Convertible & Income Fund | Convertible Securities | 0.22% | $1.6M | 1,532,000 par | $757M | NAV unavailable | Jul 31, 2026 |
| NFJ Virtus Dividend, Interest & Premium Strategy Fund | U.S. Equity | 0.13% | $1.9M | 1,760,000 par | $1.5B | 9.0% discount | Jul 31, 2026 |
| PPT Franklin Premier Income Trust | Taxable Bonds | 0.04% | $151K | 142,000 par | $390M | 9.6% discount | Jul 31, 2026 |
| PIM Franklin Master Intermediate Income Trust | Investment Grade | 0.04% | $74.6K | 66,000 par | $199M | 8.9% discount | Jun 30, 2026 |
14 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: LIGAND PHARMACEUTICALS I; Ligand Pharmaceuticals, Inc..
Related securities from the same issuer
| Security | Type | Funds holding |
|---|---|---|
| Ligand Pharmaceuticals Inc | debt security | 8 |
| Ligand Pharmaceuticals Inc | common equity | 1 |
Issuer-level search for “LIGAND PHARMACEUTICALS INC” → · Compare two funds’ portfolios →